Protalix BioTherapeutics, Inc. 4
4 · Protalix BioTherapeutics, Inc. · Filed Oct 19, 2009
Insider Transaction Report
Form 4
Shaaltiel Yoseph
DirectorExecutive VP, R&D
Transactions
- Sale
Common Stock
2009-10-16$9.39/sh−25,680$241,135→ 1,306,874 total - Sale
Common Stock
2009-10-19$9.43/sh−43,120$406,622→ 1,263,754 total - Sale
Common Stock
2009-10-15$9.39/sh−31,200$292,968→ 1,332,554 total
Footnotes (1)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan